229 related articles for article (PubMed ID: 15630505)
1. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
Capra V; Rovati GE
Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice.
Schroeter MR; Humboldt T; Schäfer K; Konstantinides S
Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832
[TBL] [Abstract][Full Text] [Related]
5. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
6. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?
Marzoll A; Melchior-Becker A; Cipollone F; Fischer JW
J Cell Mol Med; 2011 Feb; 15(2):232-43. PubMed ID: 20015203
[TBL] [Abstract][Full Text] [Related]
7. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor.
Kiyan J; Kusch A; Tkachuk S; Krämer J; Haller H; Dietz R; Smith G; Dumler I
Atherosclerosis; 2007 Dec; 195(2):254-61. PubMed ID: 17275828
[TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury.
Kappert K; Leppänen O; Paulsson J; Furuhashi M; Carlsson MA; Heldin CH; Fätkenheuer G; Rosenkranz S; Ostman A
J Acquir Immune Defic Syndr; 2006 Dec; 43(4):383-92. PubMed ID: 16967043
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat.
van der Harst P; Groenewegen HC; Roks AJ; Buikema H; Zijlstra F; van Gilst WH; de Smet BJ
Coron Artery Dis; 2008 Feb; 19(1):47-53. PubMed ID: 18281816
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition.
Werner N; Priller J; Laufs U; Endres M; Böhm M; Dirnagl U; Nickenig G
Arterioscler Thromb Vasc Biol; 2002 Oct; 22(10):1567-72. PubMed ID: 12377731
[TBL] [Abstract][Full Text] [Related]
13. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
Famer D; Crisby M
Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
[TBL] [Abstract][Full Text] [Related]
15. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis.
Grönros J; Wikström J; Brandt-Eliasson U; Forsberg GB; Behrendt M; Hansson GI; Gan LM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2046-53. PubMed ID: 18790840
[TBL] [Abstract][Full Text] [Related]
17. Enhanced effect of losartan and rosuvastatin on neointima hyperplasia.
Yi I; Lee JJ; Park JS; Zhang WY; Kim IS; Kim Y; Shin CY; Kim HS; Myung CS
Arch Pharm Res; 2010 Apr; 33(4):593-600. PubMed ID: 20422369
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of re-endothelialization and inhibition of neointimal formation using hybrid biodegradable nanofibrous rosuvastatin-loaded stents.
Lee CH; Chang SH; Lin YH; Liu SJ; Wang CJ; Hsu MY; Hung KC; Yeh YH; Chen WJ; Hsieh IC; Wen MS
Biomaterials; 2014 May; 35(15):4417-27. PubMed ID: 24582553
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
[TBL] [Abstract][Full Text] [Related]
20. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
